SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-032940
Filing Date
2024-08-19
Accepted
2024-08-19 06:30:50
Documents
70
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2050120
2 ex4-6.htm EX-4.6 33397
3 ex4-7.htm EX-4.7 30292
4 ex4-8.htm EX-4.8 29802
5 ex4-9.htm EX-4.9 30631
6 ex31-1.htm EX-31.1 18423
7 ex31-2.htm EX-31.2 17788
8 ex32-1.htm EX-32.1 7182
9 ex32-2.htm EX-32.2 7069
  Complete submission text file 0001493152-24-032940.txt   10483477

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE mymd-20240630.xsd EX-101.SCH 66933
11 XBRL CALCULATION FILE mymd-20240630_cal.xml EX-101.CAL 57463
12 XBRL DEFINITION FILE mymd-20240630_def.xml EX-101.DEF 339179
13 XBRL LABEL FILE mymd-20240630_lab.xml EX-101.LAB 542531
14 XBRL PRESENTATION FILE mymd-20240630_pre.xml EX-101.PRE 452302
73 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1918896
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36268 | Film No.: 241218212
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)